All In Biotech

Drug Trial Radar · NCT07611747

Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)

Randomized Clinical Trial to Assess the Efficacy and Safety of a Primary Prevention Strategy for Cardiovascular Events in Patients With Inflammatory Rheumatic Diseases Based on the Use of Carotid Ultrasound

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,117 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,117

Planned (sponsor's estimate)

Start

Apr 22, 2026

Primary completion

Apr 22, 2031

Study completion Dec 2031

Sponsor

Lead sponsor
Instituto de Investigación Marqués de ValdecillaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PREVENER is a randomized, open-label, multicenter, phase IV clinical trial designed to evaluate the efficacy and safety of a carotid ultrasound-based strategy for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases (IRD). Patients with IRD, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), and systemic lupus erythematosus (SLE), have a 50% higher risk of cardiovascular (CV) events compared to the general population. However, conventional CV risk scores (SCORE2/OP) systematically underestimate this risk, leaving many high-risk patients without appropriate preventive treatment. Patients aged ≥50 years with IRD and low-to-moderate CV risk according to SCORE2/OP will be randomized 1:1 to either an experimental group (carotid ultrasound to detect subclinical atherosclerosis) or a control group (standard care according to ESC 2021 guidelines). Patients in the experimental group with carotid plaques will be reclassified as very high CV risk and treated with high-intensity statins (LDL target \<55 mg/dL). The primary endpoint is the incidence of major adverse cardiovascular events (MACE) over 48 months of follow-up.

Conditions

  • Rheumatoid Arthritis (RA)
  • Psoriatic Arthritis (PsA)
  • Systemic Lupus Erythematosus (SLE)
  • Carotid Artery Diseases
  • Cardio Vascular Disease
  • Atheroscleroses
  • Axial Spondyloarthritis

Interventions

  • Carotid UltrasoundDiagnostic test

    Carotid ultrasound performed to detect subclinical atherosclerosis (carotid plaques) according to Mannheim consensus criteria. The presence of carotid plaques triggers reclassification to very high cardiovascular risk and initiation of high-intensity lipid-lowering therapy.

  • High-intensity lipid-lowering therapyDrug

    Sequential lipid-lowering therapy initiated in experimental group patients with carotid plaques, targeting LDL \< 55 mg/dL. Treatment includes high-intensity statins (atorvastatin 40-80mg, rosuvastatin 20-40mg), with possible addition of ezetimibe, bempedoic acid, and/or PCSK9 inhibitors if target is not achieved.

  • Standard care according to ESC 2021 guidelinesOther

    Lipid-lowering treatment indicated and managed according to ESC 2021 cardiovascular prevention guidelines, based on SCORE2/OP risk stratification, without carotid ultrasound assessment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Major Adverse Cardiovascular Events (MACE)Time frame: 48 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Araba

    Vitoria-Gasteiz, Álava, Spain · Recruiting

  • Hospital Universitario de Elche

    Elche, Alicante, Spain · Recruiting

  • Hospital Vega Baja de Orihuela

    Orihuela, Alicante, Spain · Recruiting

  • Hospital Universitario San Juan de Alicante

    Sant Joan d'Alacant, Alicante, Spain · Recruiting

  • Hospital Universitario Vall d'Hebrón

    Barcelona, Barcelona, Spain · Recruiting

  • Hospital de Laredo

    Laredo, Cantabria, Spain · Recruiting

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, Spain · Recruiting

  • Hospital Sierrallana

    Torrelavega, Cantabria, Spain · Recruiting

  • Hospital General Universitario de Ciudad Real

    Ciudad Real, Ciudad Real, Spain · Recruiting

  • Hospital Universitario Reina Sofía

    Córdoba, Córdoba, Spain · Recruiting

  • Hospital Universitari Son LLàtzer

    Palma, Isla Baleares, Spain · Recruiting

  • Hospital Universitario de Gran Canaria Dr. Negrín

    Las Palmas de Gran Canaria, Las Palmas, Spain · Not yet recruiting

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario Virgen de la Arrixaca

    Murcia, Murcia, Spain · Recruiting

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain · Recruiting

  • Hospital Universitario de Basurto

    Bilbao, Vizcaya, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.